JBJ-08-178-01
JBJ-08-178-01 is a mutant-selective tyrosine kinase inhibitor against human epidermal growth factor receptor 2 (HER2) with an antitumoral activity. JBJ-08-178-01 reduces both the kinase activity and protein levels of HER2 by inducing proteasomal degradation of the receptor in lung cancer. JBJ-08-178-01 is promising for research of non-small-cell lung cancer[1][2][3].
Product Specifications
CAS Number
2401867-58-9
UNSPSC
12352005
Target
Proteasome
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/jbj-08-178-01.html
Smiles
CC1=CC(NC2=C3C=C(NC(/C=C/CN(C)C)=O)C(OCC)=CC3=NC=C2C#N)=CC=C1OC4=CC5=NC=NN5C=C4
Molecular Formula
C31H30N8O3
Molecular Weight
562.62
References & Citations
[1]Rubin E, et al. Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers. Int J Mol Sci. 2024 Jan 15;25 (2) :1064. |[2]Vathiotis IA, et al. Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond. Cancers (Basel) . 2023 Feb 17;15 (4) :1286.|[3]Son J, et al. A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non-Small Cell Lung Cancer. Cancer Res. 2022 Apr 15;82 (8) :1633-1645.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
abx231059 100 µg
Innate Immunity Activator Protein (INAVA) Antibody
Sign In for Pricing
View Details 
TMPH-03639-01 5 µg
COX7A1 Protein, Trachypithecus cristatu, Recombinant (hFc)
Sign In for Pricing
View Details TMPH-03639-02 10 µg
COX7A1 Protein, Trachypithecus cristatu, Recombinant (hFc)
Sign In for Pricing
View Details